This is a working overview of freeze-thaw, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-14. Anything still debated is marked as such rather than presented as settled.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
== Product life cycle approach in validation == Validation process efforts must account for the complete product life cycle, including developmental procedures adapted for qualification of a drug product commencing with its research and development phase, rationale for adapting a best fit formula which represents the relationship between required outputs and specified inputs, and procedure for manufacturing. Each step is required to be justified and monitored in order to provide a good quality food and drug product. The FDA emphasizes the product life cycle approach in its evaluation of manufacturer regulatory compliance as well.
Pure water is visibly blue due to absorption of light in the region c. 600–800 nm. The color can be easily observed in a glass of tap-water placed against a pure white background, in daylight. The principal absorption bands responsible for the color are overtones of the O–H stretching vibrations. The apparent intensity of the color increases with the depth of the water column, following Beer's law. This also applies, for example, with a swimming pool when the light source is sunlight reflected from the pool's white tiles. In nature, the color may also be modified from blue to green due to the presence of suspended solids or algae. In industry, near-infrared spectroscopy is used with aqueous solutions as the greater intensity of the lower overtones of water means that glass cuvettes with short path-length may be employed. To observe the fundamental stretching absorption spectrum of water or of an aqueous solution in the region around 3,500 cm−1 (2.85 μm) a path length of about 25 μm is needed. Also, the cuvette must be both transparent around 3500 cm−1 and insoluble in water; calcium fluoride is one material that is in common use for the cuvette windows with aqueous solutions. The Raman-active fundamental vibrations may be observed with, for example, a 1 cm sample cell. Aquatic plants, algae, and other photosynthetic organisms can live in water up to hundreds of meters deep, because sunlight can reach them. Practically no sunlight reaches the parts of the oceans below 1,000 metres (3,300 ft) of depth.
== Context == Leonard P. Guarente is recognized as the leading proponent of the hypothesis that caloric restriction slows aging by activation of Sirtuins. STACs have been discovered by Konrad Howitz of Biomol Inc and biologist David Sinclair. In September 2003, Howitz and Sinclair et al. published a highly cited paper reporting that polyphenols such as resveratrol activate human SIRT1 and extend the lifespan of budding yeast (Howitz et al., Nature, 2003). Other examples of such products are butein, piceatannol, isoliquiritigenin, fisetin, and quercetin. Sirtuins depend on the crucial cellular molecule called nicotinamide adenine dinucleotide (NAD+) for their function. Falling NAD+ levels during aging may adversely impact sirtuin maintenance of DNA integrity and ability to combat oxidative stress-induced cell damage. Increasing cellular NAD+ levels with supplements like nicotinamide mononucleotide (NMN) during aging may slow or reverse certain aging processes with sirtuin function enhancement. Some STACs can cause artificial effects in the assay initially used for their identification, but it has been shown that STACs also activate SIRT1 against regular polypeptide substrates, with an influence of the substrate sequence. Sirtris Pharmaceuticals, Sinclair's company, was purchased by GlaxoSmithKline (GSK) in 2008, and subsequently shut down as a separate entity within GSK.
Sources: en.wikipedia.org
On 9 January 2024, the Kata'ib Hezbollah spokesperson Jafar al-Husseini warned that the Islamic Resistance in Iraq would help Hezbollah fight Israel if war erupted between the two sides. This statement was a few weeks after the Islamic Resistance in Iraq claimed responsibility for a drone attack on a Karish rig which Lebanon claims to hold sovereignty to. On 23 June 2024, the spokesperson to Kata'ib Sayyid al-Shuhada Kadhem al-Fartousi said the brigade will join Hezbollah's side if Israel decides to launch a full-blown war in Lebanon. On 24 June 2024, Qais al-Khazali, the leader of Asa'ib Ahl al-Haq, stated in a televised speech that if the U.S. continued to support Israel in expanding the war to Lebanon and Hezbollah, the group would begin to attack US interests in Iraq and the Middle East.
==== Space disposal ==== Space disposal is attractive because it removes nuclear waste from the planet. It has significant disadvantages, such as the potential for catastrophic failure of a launch vehicle, which could spread radioactive material into the atmosphere and around the world. A high number of launches would be required because no individual rocket would be able to carry very much of the material relative to the total amount that needs to be disposed. This makes the proposal economically impractical and increases the risk of one or more launch failures. To further complicate matters, international agreements on the regulation of such a program would need to be established. Costs and inadequate reliability of modern rocket launch systems for space disposal has been one of the motives for interest in non-rocket spacelaunch systems such as mass drivers, space elevators, and other proposals.
== Time of maximum daughter activity == In transient equilibrium, the daughter activity increases and eventually reaches a maximum value that can exceed the parent activity. The time of maximum activity is given by:
Sources: en.wikipedia.org
== Medical uses == The spectrum of action includes many Gram-positive and Gram-negative bacteria (including Pseudomonas) and anaerobic bacteria. The overall spectrum is similar to that of imipenem, although meropenem is more active against Enterobacteriaceae and less active against Gram-positive bacteria. Meropenem is effective against bacteria producing extended-spectrum β-lactamases but may be more susceptible to hydrolysis by metallo-β-lactamases produced by bacteria. β-lactamases are enzymes that bacteria produce to hydrolyze β-lactam antibiotics, breaking the β-lactam ring and rendering these antibiotics ineffective. This mechanism helps bacteria resist the effects of antibiotics like penicillins, cephalosporins, and carbapenems, making treatment more challenging. While β-lactam ring in meropenem is more accessible to water molecules than in the other β-lactam antibiotics, that facilitates the hydrolysis process and faster degradation of meropenem's antibacterial properties in aqueous solutions, it is more resistant to degradation by β-lactamase enzymes produced by bacteria than the other β-lactam antibiotics. Meropenem is frequently given in the treatment of febrile neutropenia. This condition frequently occurs in patients with hematological malignancies and cancer patients receiving anticancer drugs that suppress bone marrow formation. Meropenem is approved for complicated skin and skin structure infections, complicated intra-abdominal infections and bacterial meningitis. Meropenem is effective in treating bacterial pneumonia, including hospital-acquired pneumonia.
The correct molecular structure is prominently ranked from an extensive list of candidates. This can be compared to a Google search where the optimal answer is expected to be among the top three. It can be assessed whether the top candidate is indeed correct. Structural information is available even for molecules absent in extensive structure databases, including de novo candidate structures, details on compound class and substructure information.
In accordance with such findings, high-dose CPA shows equivalent effects on the prostate gland in men relative to high-dose diethylstilbestrol or buserelin, which both achieve castrate levels of testosterone. However, a lower dosage of 50 mg/day CPA has been found to produce a reduction in prostate volume in men with benign prostatic hyperplasia that is reportedly comparable to that observed with surgical or medical castration. In accordance, the dosage of CPA that achieves complete inhibition of the secretory function of the healthy prostate gland is around 50 to 100 mg/day, which is less than the dosage of 200 to 300 mg/day CPA that is used to treat prostate cancer. It has been said that in combined androgen blockade regimens with castration and CPA as the AR antagonist for prostate cancer, due to the marked reduction in androgen levels, lower dosages of CPA than those used as a monotherapy would seem to be equally effective. Relative to the 200 to 300 mg/day dosage of CPA used as a monotherapy in prostate cancer, the recommended dosage in combined androgen blockade is 100 to 200 mg/day. It has been stated that this dosage should be more than necessary to inhibit the effects of the remaining adrenal androgens in castrated men. Despite considerable suppression of testosterone levels, only a modest suppression of spermatogenesis typically occurs with 5 to 10 mg/day CPA, and azoospermia occurs only occasionally. Conversely, a combination of testosterone enanthate injections with 12.5 to 100 mg/day CPA results in azoospermia in most men.
Cyclone Tam causes significant power outages in Northland and leads to the cancellation of flights and ferry services in Auckland. 17 April – Cyclone Tam causes over 6,000 properties in Northland, the Coromandel Peninsula, Bay of Plenty and Gisborne to lose power overnight. 18 April – Cyclone Tam causes flooding to roads and highways in the Coromandel Peninsula. Flooding and strong-winds are also reported in the Far North District, leading to road closures and flight disruptions. 19 April – Cyclone Tam causes flooding, thunderstorms and travel disruptions in Auckland. Local authorities issue an emergency alert. 20 April: Auckland authorities issue a second emergency alert in response to flooding and thunderstorms caused by Cyclone Tam. 70 protesters affiliated with the Happy Valley Coalition occupy a fast-tracked coal mine on the Denniston Plateau near Westport. 21 April – Cyclone Tam begins easing, despite heavy rain and thunderstorms across New Zealand. Power companies work on restoring power to Northland homes. The Auckland Council inspects 16 flood-damaged properties. 22 April – Power companies restore power to most houses in Northland, with 25 Far North homes remaining disconnected. 23 April – Police remove the last remaining protesters from a coal mine in the Denniston Plateau. Seven people were charged with trespassing while three were arrested. 24 April – A fire breaks out at a recycling plant in the Wairau Valley in Auckland's North Shore, causing significant damage including a chemical spill contaminating several beaches in the North Shore.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.